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Abstract The proinflammatory cytokine osteopontin (OPN)
is elevated in the cerebrospinal fluid (CSF) in individuals with
HIV-associated neurocognitive disorders (HAND) and re-
mains so in those on suppressive antiretroviral therapy. To
understand the pathophysiological significance of elevated
OPN in the CNS, we sought to determine the cellular source
of this cytokine. As HIV-1 replicates productively in macro-
phages/microglia, we tested whether these cells are the pre-
dominant producers of OPN in the brain. Stringent patient
selection criteria, which excluded brain tissues from those
with evidence of drug abuse and dependence, were used.
Uninfected normal controls, amyotrophic lateral sclerosis
(ALS), HIV+ asymptomatic neurocognitive impairment
(ANI), and HIV+ mild neurocognitive disorder (MND)/HIV-
associated dementia (HAD) groups were included. Double-
label immunohistochemistry for CNS cells and OPNwas used
to quantify OPN expression in astrocytes, macrophages/mi-
croglia, and neurons. While resident macrophages/microglia
expressed OPN, astrocytes and unexpectedly neurons were
also a major source of OPN. OPN levels in ionized Ca2+-
binding adapter 1 (Iba1)/allograft inflammatory factor-1
(AIF-1)+ microglia in HIV+ ANI and MND/HAD exceeded
those of HIV-negative controls and were comparable to ex-
pression seen in ALS. Moreover, in neurons, OPN was
expressed at the highest levels in the HIV+ ANI group.
These findings suggest that while infiltrating HIV-infected
macrophages are most likely the initial source of OPN, resi-
dent CNS cells become activated and also express this inflam-
matory cytokine at significant levels. Moreover, as OPN
levels are elevated compared to uninfected individuals and
increases with the severity of impairment, it appears that the
expression of OPN is persistent and sustained within the brain
parenchyma in those that progress to HAND.
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Introduction
Trafficking of HIV-infected macrophages and activated unin-
fected monocytes/macrophages into the brain occurs early in
the course of viral infection (Budka et al. 1987; Davis et al.
1992; Glass et al. 1995; Koenig et al. 1986) and initiates the
seeding of resident brain macrophages, microglia, and astro-
cytes with HIV/SIV DNA (Clements et al. 2002). The local
immune response in the brain results in an inflammatory mi-
lieu that exacerbates the release of substances including glu-
tamate leading, by mechanisms that remain to be fully eluci-
dated, to neurotoxicity, neuronal dysfunction, and cognitive
impairment collectively known as HIV-associated
neurocognitive disorders (HAND) (Kraft-Terry et al. 2010;
Vázquez-Santiago et al. 2014). HAND is assessed through a
battery of neuropsychological tests and encompasses three
levels of impairment: asymptomatic neurocognitive impair-
ment (ANI), HIV-associated mild neurocognitive disorder
(MND), and HIV-associated dementia (HAD) (Antinori
et al. 2007). The prevalence of HIV-associated neurocognitive
disorders and particularly the milder forms has increased,
while the incidence of severe debilitating dementia has dra-
matically decreased (McArthur et al. 2010). This latter finding
reflects the high efficacy of suppressing HIV replication,
which results in significant reductions in viral load in the
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blood and cerebrospinal fluid (CSF) with combination antire-
troviral therapy (ART) that target two ormore steps in the viral
life cycle. However, in up to 50% of HIV-infected individuals
on ART, cognitive dysfunction remains a significant problem
(Heaton et al. 2010; Heaton et al. 2011), and currently, no
adjunctive neuroprotective therapies have yet reached routine
clinic practice (Meulendyke et al. 2014).
Several potential explanations have been proposed to ex-
plain the continued impairment including the inefficient pen-
etration of ART into the brain parenchyma that would permit
low-level ongoing viral replication at this site, toxicity of ART
and its metabolites (Tovar-y-Romo et al. 2012), and comor-
bidities including aging and cardiovascular disease could all
potentially contribute to the continued dysfunction seen in
HIV-infected individuals (Deeks et al. 2013). Additionally,
markers of immune activation remain elevated in the periph-
ery and CNS in even the most well-suppressed HIV-infected
ART-treated individuals, suggesting the continued stimulation
and hyperactivity of the immune system to antigens from sev-
eral anatomical locations including the intestine (Brenchley
et al. 2006; Spudich et al. 2011). Inflammation in the brain
in response to injury or invasion by microorganisms can play
either beneficial and/or neuropathogenic roles depending on
the intensity and duration of the response (Katsumoto et al.
2014).
Osteopontin (OPN), a proinflammatory cytokine of the in-
nate immune system, was first reported to be increased in the
brains of SIVE-infected macaques and later in the plasma,
CSF, and brains of HIV-infected individuals with cognitive
impairment (Brown et al. 2011; Burdo et al. 2008). A recent
study suggests that OPN remains elevated in plasma in those
on ART (Burdo et al. 2011). Interestingly, OPN is elevated in
other neurodegenerative disorders including multiple sclerosis
(MS), Alzheimer’s disease, Parkinson’s disease, and
frontotemporal dementia (Braitch et al. 2008; Chabas et al.
2001; Comabella et al. 2005; Comi et al. 2010; Iczkiewicz
et al. 2006; Maetzler et al. 2007; Mattsson et al. 2008;
Wirths et al. 2010). Only in the case of MS has the role of
OPN been explored where in mouse models of the disorder,
OPN has been shown to facilitate the survival of anti-myelin
autoreactive T cells (Hur et al. 2006; Jansson et al. 2002). We
have shown that OPN is significantly elevated in HIV-infected
macrophages (Brown et al. 2011). Inhibition of OPN in mac-
rophages with siRNA inhibits HIV replication 50 % suggest-
ing that OPN stimulates viral replication likely through a
NF-κB-dependent mechanism acting via OPN receptors, thus
forming a feedback loop which promotes continued cellular
activation and viral spread (Brown et al. 2011; Eger et al.
2014). Because of their central role in the development of
HIV-associated cognitive impairment, and to gain an under-
standing of the impact of activated HIV-infected macrophages
on the expression of OPN in the context of the central nervous
system (CNS), we used double-label immunochemistry for
cells of the human brain and OPN to test the hypothesis that
resident macrophages/microglia are the major sources of this
proinflammatory cytokine associated with HAND. Four
groups of brain tissue were compared including normal,
HIV-uninfected controls, HIV-positive with ANI, HIV-
positive MND/HAD, and a group with amyotrophic lateral
sclerosis (ALS). ALS is a progressive motor neuron degener-
ative disorder, in which macrophage and microglial activation
is now thought to be involved in the pathological progression
of the disease. Moreover, recent studies suggest that
microglial activation may be associated with deficits in exec-
utive function (Brettschneider et al. 2012a; Brites and Vaz
2014). As such, ALS samples were included as a Bneurode-
generative other^ control. While astrocytes and resident
macrophage/microglia express OPN, to our surprise we found
that in addition, neurons significantly contribute to the pool of
OPN found in the brain in individuals with HAND. These
findings suggest that while HIV-infected macrophages stimu-
late the initial increase of OPN in the brain, resident macro-
phage/microglia, astrocytes, as well as neurons overexpress
this cytokine. As all of these cells express the receptors for
OPN (Ailane et al. 2013; Akiyama et al. 1993), our findings
suggest that microglial, astrocytic, and neuronal activity and
function can potentially be directly altered by OPN through
paracrine regulatory mechanisms as a result.
Results
Patient samples and clinical characteristics
Microarray analyses on the brains of SIV-infected macaques
identified numerous genes including osteopontin (OPN) that
were differentially regulated (Roberts et al. 2003). Further
investigations found that OPN was significantly elevated in
the plasma of rhesus macaques and CSF and brain in individ-
uals with HAND (Brown et al. 2011; Burdo et al. 2008; Eger
et al. 2014). Burdo et al. proposed HIV-infected and/or acti-
vated macrophage trafficking into the brain releases OPN,
which has chemotactic and antiapoptotic signaling potential,
and serves in a feedback loop fueling the establishment of
HIV in the brain as well as the cellular activation and inflam-
mation at this site (Burdo et al. 2007). To better understand the
potential neuropathogenic role for elevated OPN in HAND, in
this study, we tested the hypothesis that activated
macrophages/resident microglia are the cellular sources of
OPN in the brain. Stringent patient sample criteria were used
including the exclusion of the drugs of abuse cocaine, canna-
bis, opiate, and methadone. In addition, toxicology reports
were examined to exclude drug abuse and dependence. We
used double-label immunohistochemistry and antibodies to
CD68 and Iba-1/AIF-1 to specifically identify macrophage/
microglia in brain tissue from uninfected controls, HIV+
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ANI, HIV+MND/HAD, and a group with a well-known neu-
rodegenerative disease affecting motor neurons, amyotrophic
lateral sclerosis, ALS. Moreover, as astrocytes and neurons
have been reported to express increased levels of OPN in
models of brain injury and neurodegeneration, we also used
anti-glial fibrillary acidic protein (GFAP) and anti-neuronal
nuclei (NeuN) antibodies to determinewhether this proinflam-
matory cytokine is elevated in these cell types. The demo-
graphics and clinical parameters of the patients used are
shown in Table 1. There were no significant differences
in age of the subjects in each group (normal, 47.7±
7.35; ALS, 50.4±7.37, HIV ANI 43.4±7.89; HIV
NMD/HAD, 40.5±10.5).
Osteopontin is significantly elevated in GFAP-reactive
astrocytes from HIV+ MND/HAD cases compared to ALS
samples
GFAP reactivity was highest in the upper cortical layers in
most samples and in some cases, positively stained cells were
visible throughout all cortical layers (Fig. 1). In the HIV+
MND/HAD group, astrocytic cell bodies devoid of processes
often predominated (Fig. 1, cases 19 and 20). Compared to the
normal control group (0.612±0.255, n=9), OPN levels did
not differ significantly with the other groups (HIV + NC,
0.576±0.212, n=5; HIV+ impaired, 0.682±0.254, n=5;
ALS, 0.524±0.207, n=5), although there was a trend of
Table 1 Patient sample demographics
Patient ID Age Sex Race HIV status Neurocog diagnosis Plasma VL CSF VL CD4 ARV
Case 1 47 F Black Neg Normal NA NA NA NA
Case 2 44 F White Neg Normal NA NA NA NA
Case 3 51 M White/Hispanic Neg Normal NA NA NA NA
Case 4 49 M White Neg Normal NA NA NA NA
Case 5 46 M White Neg Normal NA NA NA NA
Case 6 39 M Hispanic Pos ANI 570 <50 79 Yes
Case 7 43 M White Pos ANI 249 19 7 Yes
Case 8 39 M White Pos MND 72,125 70 1 Yes
Case 9 33 M Hispanic Pos MND 400 NT 11 Yes
Case 10 35 M White Pos MND/HAD (HIVE) 2827 78 211 Yes
Case 11 37 M White Pos MND 178 5968 85 Yes
Case 12 31 M White Pos MND 483,758 148 10 Yes
Case 13 57 M Asian Pos HAD 40,133 2747 299 Yes
Case 14 30 F Hispanic Neg Normal NA NA NA NA
Case 15 48 F Hispanic Neg Normal NA NA NA NA
Case 16 50 M Hispanic Neg Normal NA NA NA NA
Case 17 56 F White Neg NA NA NA NA NA
Case 18 57 M Black Pos MND 63,953 NT 194 Yes
Case 19 34 M White Pos ANI >750,000 NT 9 Yes
Case 20 46 M White Pos ANI <50 <50 233 Yes
Case 21 45 M Hispanic Pos MND/HAD 628 376 28 Yes
Case 22 31 F Hispanic Pos MND/HAD 744,349 NT 4 Yes
Case 23 55 F Black Pos ANI 37,060 NT 114 Yes
Case 24 56 F White Neg Normal NA NA NA NA
Case 25 38 M White Neg ALS NA NA NA NA
Case 26 53 F White Neg ALS NA NA NA NA
Case 27 50 M White Neg ALS NA NA NA NA
Case 28 54 M White Neg ALS NA NA NA NA
Case 29 57 F Hispanic Neg ALS NA NA NA NA
Data are from last clinic visit. Age at death
NA not applicable, NT not available, HIV Neg seronegative, HIV Pos seropositive, VL viral load, ARV antiretroviral use, ANI asymptomatic
neurocognitive impairment, MND minor neurocognitive disorder, HAD HIV-associated dementia, ALS amyotrophic lateral sclerosis
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increased OPN in the HIV+ MND/HAD group (Fig. 2a). A
significant increase in the level of OPN between the HIV+
MND/HAD and the ALS group was detected (p=0.011,
Fig. 2). Normalization of GFAP levels to OPN revealed no
significant differences in the expression of GFAP among the
different groups (Fig. 2b; normal, 2.02±1.10; HIV + ANI,
2.027±0.898; HIV+ MND/HAD 1.722±0.792; ALS, 2.231±
0.948). These results suggest that GFAP-reactive astrocytes in
HAND express OPN, and while levels between HIV+ NC and
HIV+ MND/HAD did not differ, astrocytes in the latter case
produce significantly higher levels of OPN than what was seen




Fig. 1 Osteopontin (OPN)
expression in GFAP+ astrocytes.
Paraffin-embedded human
autopsy tissue from the occipital
lobe of cases and controls from
the National NeuroAIDS Tissue




phosphatase (AP) secondary and
developed with permanent Fast-
Red Quanto (red) then reacted
with mouse monoclonal antibody
to OPN/goat anti-mouse-horse
radish peroxidase and developed
with 3,3′-diaminobenzidine. a
case 14, normal control; b case
29, amyotrophic lateral sclerosis
(ALS); c case 19, asymptomatic
neurocognitive disorder (ANI); d
case 20, ANI; e case 21, minor
neurocognitive disorder/HIV-
associated dementia (MND/
HAD); f case 22, MND/HAD
a b
Fig. 2 Osteopontin is significantly elevated in GFAP-reactive astrocytes
from HIV+ MND/HAD cases compared to amyotrophic lateral sclerosis
(ALS) samples. Ten images were taken at ×20magnification from all four
quadrants of the slides for each case (an equal amount of area), and the
intensity (area fraction) of the label for OPN and GFAP were quantified
using ImageJ. The results are expressed as the ratio of aOPN to GFAP or
bGFAP to OPN. One-way ANOVA, with Tukey’s correction for multiple
comparisons and significance of *p<0.05, was determined with
GraphPad Prism 6. Normal, ALS, amyotrophic lateral sclerosis, HIV-
infected cases asymptomatic neurocognitive disorder (HIV+ ANI), and
HIV-infected cases with minor neurocognitive disorder/HIV-associated
dementia (HIV+ MND/HAD)
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Microglial osteopontin levels are significantly increased
in HAND and ALS
Microglia stained for Iba-1/AIF-1 displayed a variety of mor-
phologies including ramified and ameboid shapes with vary-
ing degrees of processes (Fig. 3). Unexpectedly, abundant
Iba-/AIF-1 staining was seen in several samples from the nor-
mal control group (Fig. 3a–b, cases 16 and 4). In addition,
there was abundant Iba-1/AIF-1 reactivity in samples from
the ALS group with distinctive labeling of microglia with
extended ramified shapes (Fig. 3c, case 29). OPN levels in
microglia were significantly elevated compared to normal
controls (0.758±0.376, n=9) for ALS (1.356±0.848,
p<0.0001, n=5), HIV+ ANI (1.463±0.934, p<0.0001, n=
5), and HIV+ MND/HAD (1.467±0.721, p<0.0001, n=5),
but there were no differences between the disease groups
(Fig. 4a). The level of Iba-I/AIF-1 normalized to OPN inten-
sity was significantly lower in the disease groups (HIV+ ANI,
0.969±0.570, p<0.0001; HIV+ MND/HAD, 0.829±0.358,
p<0.0001; ALS, 1.094±0.782, p<0.0001) compared to the
normal controls (1.741±1.21) (Fig. 4b). These results suggest
that the amount of OPN expression per microglia was signif-
icantly elevated in the diseased groups compared to the nor-
mal controls.
Osteopontin levels in cortical neurons are significantly
elevated in HIV-infected individuals with ANI compared
to HIV-infected cases with cognitive impairment
(MND/HAD) or ALS
In HIV+ and ALS samples, NeuN reactivity was local-
ized in the nucleus as well as in the cytoplasm (Lucas
et al. 2014), while OPN staining was restricted to the
cy top l a sm of neu rona l c e l l bod i e s (F ig . 5 ) .
Unexpectedly, abundant OPN reactive NeuN+ neurons
were readily detectable in many of the normal uninfect-
ed controls (Fig. 6a). OPN levels were highest in the
HIV+ ANI cases (1.706±1.045, n=6) compared to all
other groups (normal, 1.394±0.748, p=0.005, n=10;
HIV+ MND/HAD, 1.428±0.589, p=0.023, n=8; ALS,
1.226±0.862, p<0.0001, n=5) (Fig. 7). Based on the
NeuN/OPN ratio, the ALS group (1.134±0.632) had
significantly more NeuN-reactive neurons compared to
the normal (0.93±0.59, p=0.018), HIV+ ANI (0.844±
0.614, p=0.001), and HIV+ MND/HAD groups (0.836±
0.438, p=0.0002), which were similar to each other
(Fig. 7b). These results suggest that neurons in cases





Fig. 3 Osteopontin (OPN)
expression in Iba1/AIF-1+
microglia. See staining paradigm
as given in figure legend 1. a case
16, normal; b case 4, normal; c
case 29, ALS; d case 23, ANI; e
case 12, MND; f case 13, HAD
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CD68+ macrophages/microglia are readily detectable
in normal control samples
The high level of OPN, GFAP, and Iba-1/AIF-1 expression seen
in the normal control group suggested the presence of injury
and/or inflammation in the brain. To investigate this possibility,
we stained sections with anti-CD68, which detects microglia, as
well as perivascular, parenchymal, and resident macrophages
(Esiri and McGee 1986), which typically have a finite lifespan
in the brain and are not present in large numbers under normal
homeostatic conditions (Esiri and O’D McGee 1986; Fischer-
Smith et al. 2004). Strikingly, in 8 out of 10 normal cases,
CD68+ macrophages/microglia were readily detectable
throughout the cortical layers (Fig. 8). The level of CD68 reac-
tivity was similar to or significantly exceeded that of HIV+
MND/HAD samples (case 1 vs. case 21, p=0.0026; case 1 vs.
case 22, p=0.0101; case 14 vs. case 21, p=0.0287; Fig. 9).
Table 2 lists the cause of death for samples in the normal control
group. In several cases, severe injury to the gastrointestinal tract
(Fig. 9, cases 1, 4, and 24) and disorders of the lungs (Fig. 9,
cases 2, 5, and 14) displayed the highest levels of CD68 staining,
although there were no statistically significant differences be-
tween the normal samples with the exception of case 17 vs. case
1 (p=0.0368). These results suggest that the majority of normal
controls used in this study, although not infected with HIV,
displayed evidence of exposure to an event(s) that promoted a
sustained increase of CD68+ macrophages in the brain.
Discussion
The high level of OPN staining in GFAP+ astrocytes and
NeuN+ neurons in the HIV-uninfected control group was very
a b
Fig. 4 Microglia-associated osteopontin levels are significantly
increased in HAND and ALS. See description of quantification scheme
given in figure legend 2. The results are expressed as the ratio of aOPN to
Iba1/AIF-1 or b Iba1/AIF-1 to OPN. One-way ANOVA, with Tukey’s
correction for multiple comparisons and significance of p<0.05, was
determined with GraphPad Prism 6. Normal, ALS, amyotrophic lateral
sclerosis, HIV-infected cases asymptomatic neurocognitive disorder
(HIV+ ANI), and HIV-infected cases with minor neurocognitive
disorder/HIV-associated dementia (HIV+ MND/HAD); ****p<0.0001
a
b
Fig. 5 NeuN reactivity is localized to the nucleus and cytoplasm, while
OPN is restricted to the cytoplasm of neuronal cell bodies. Image label
intensity for NeuN and OPN reactivity in double-stained sections were
analyzed using ImageJ. Top panel, threshold for NeuN positivity. Lower
panel, threshold for anti-OPN staining within neurons
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surprising. For these types of studies, normal controls present
several limitations: they are less plentiful and more difficult to
obtain, and specific clinical data most relevant to the study is
often not available. The presence of a high concentration of
CD68+ macrophage/microglia strongly suggests that these
brains experienced injury and/or pathogenic sequela, which
resulted in an inflammatory response. In fact, there is now







Fig. 6 Double-labeled neurons
expressing NeuN and OPN. See
staining paradigm as given in
figure legend 1. a case 16,
normal; b case 25, ALS; c case
18, MND; d case 20, ANI; e case
21, MND/HAD; f case 13, HAD
a b
Fig. 7 Osteopontin levels in cortical neurons are significantly elevated in
HIV-infected individuals with asymptomatic neurocognitive impairment
(ANI) compared to HIV-infected cases with cognitive impairment (MND/
HAD) or ALS. See description of quantification scheme given in figure
legend 2. The results are expressed as the ratio of a OPN to NeuN,
****p<0.0001, **p=0.0052, *p=0.0232, or b NeuN to OPN,
****p<0.0001, ***p=0.0002, **p=0.0011, *p=0.0181. Normal, ALS,
amyotrophic lateral sclerosis, HIV-infected cases asymptomatic
neurocognitive disorder (HIV+ ANI), and HIV-infected cases with
minor neurocognitive disorder/HIV-associated dementia (HIV+
MND/HAD)
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injury in the kidneys, lungs, and gastrointestinal tract and in-
flammation in the central nervous system (Bémeur and
Butterworth 2013; Hilzendeger et al. 2014; Winterberg and
Lu 2012). While all attempts are made to select the most










Fig. 8 Presence of CD68+
macrophages/microglia in normal
and MND/HAD groups. See
staining paradigm as given in
figure legend 1. a case 14,
normal; b case 24, normal; c case
16, normal; d case 1, normal; e
case 17, normal; f case 5, normal;
g case 2, normal; h case 11,
MND; and i case 13, HAD
Fig. 9 CD68+ macrophages/microglia are readily detectable in normal
control samples. ImageJ was used to quantify the area fraction of CD68
reactivity in three representative fields from each case. The mean and
standard deviation and level of significance as determined by one-way
ANOVA for normal controls and MND/HAD cases are shown. Category
of clinical disorders (Table 2) at the time of death is indicated above the
appropriate bars: GI gastrointestinal related, HCV hepatitis C virus
Table 2 Clinical indications at the time of death
Patient
ID
Disorders at time of death
Case 1 Upper GI bleed from ruptured esophageal varices;
autoimmune hepatitis, ANA+ arthritis
Case 2 Tension pneumothorax most likely due to puncture of lung
Case 3 Multi-organ failure secondary to cardiogenic shock due to
myocardial infarction in a failing heart with prior ischemic
damage
Case 4 Hemorrhagic shock due to gastrointestinal bleeding from a
large duodenal ulcer that destroyed a segment of the
tastroduodenal artery; peptic ulcer disease
Case 5 Severe necrotizing tracheobronchitis and pneumonia due to
community acquired-MRSA and beta hemolytic
Streptococcus group B
Case 14 Severe mitral valvular disease with calcified bioprosthesis and
calcific, infected emboli to multiple organs (consistent with
strep pneumoniae); end-stage renal disease;
bronchopneumonia
Case 15 Hepatitis C cirrhosis and end stage liver disease; staph aureus
sepsis; prior IVDU
Case 16 Klebsiella sepsis with hepatic abscess, OLT for HCV cirrhosis,
pulmonary hypertension, ECRP with sphincterotomy for
biliary stones
Case 24 Scleroderma with CREST syndrome, GI hypomotility with
large bowel obstruction, subtotal colectomy, erosive
candidal esophagitis, and pneumoatosis intestinalis small
intestine; pulmonary fibrosis, hypertension, and
emphysema; arterionephrosclerosis; cachexia
Case 17 Ovarian cancer
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working with human clinical samples. Perhaps prescreening
of normal controls for specific inflammatory markers could be
used to select tissues with low levels of baseline activation. It
should be noted that the samples in this study differed from
those used in a prior report on OPN levels in the CSF (Brown
et al. 2011).
Despite the possible limitations of the control samples used
in this study, OPN was expressed at a significantly higher
level in Iba-1/AIF-1+ microglia in both the HIV+ ANI and
HIV+ MND/HAD groups suggesting that these cells are a
major source of this proinflammatory cytokine in the brain.
The HIV+ samples came from individuals who were on ART,
yet elevated OPN levels appeared to be sustained over a peri-
od of many years. A recent study analyzing traditional
markers of cellular activation using brain tissue from the fron-
tal white matter and basal ganglia of HIV-infected individuals
on ART with cognitive impairment, but no encephalitis, also
found that inflammation persists in those without HIVenceph-
alitis despite therapy (Tavazzi et al. 2014). Elevation of
CD68+ macrophage/microglia in the absence of any evidence
of local proliferation in autopsy samples from the hippocam-
pus of individuals on highly active antiretroviral therapy com-
pared to normal controls was seen in a study by Anthony et al.
suggesting that these cells remain activated despite the effec-
tive suppression of HIV replication (Anthony et al. 2005).
However, unlike our study, many of the samples were from
individuals who abused drugs (and were HCV+), a potential
contributor to neuroinflammation (Anthony et al. 2005).
Moreover, in the current study, 11 out of the 14 HIV-
infected individuals, irrespective of detectable viral load in
the plasma or CSF, were very immunosuppressed as deter-
mined by a CD4+ T cell level below 200 cells/ml (Table 1).
In 50 % of the HIV+ cases, viral load was detected in the CSF
suggesting the real possibility that persistent viral replication
albeit at varying levels continued within the brain
parenchyma.
Ionized Ca2+-binding adapter 1 (Iba1), which is thought to
be the same gene product as allograft inflammatory factor-1
(AIF-1), is a 17-kDa cytoplasmic protein that binds calcium
whose function continues to be elucidated (Zhao et al. 2013).
While Iba-1/AIF-1 is expressed constitutively, it can also be a
marker of the cellular inflammatory response as it sits in a
gene cluster with TNF-α, TNF-β, and NF-κB in the MHC
class III region (Zhao et al. 2013). Both ameboid and ramified
microglia morphologywas observed inmost cases. Both types
of microglia possess phagocytic activity and the ability to
clear debris, while those with a ramified shape have been
reported to contribute to efficient neurogenesis and the main-
tenance of synapses (Paolicelli et al. 2014; Perry and Teeling
2013). In the HIV+MND/HAD group, microglia without any
processes, which may be the ameboid type, often predominat-
ed suggesting that they are actively involved in phagocytosis
and the clearance of dying cells. Alternatively, the absence of
microglia with ramified morphology could indicate a func-
tional deficit in the ability to conduct the high-level surveil-
lance that is characteristic of microglia in the unimpaired brain
(Nimmerjahn et al. 2005). In this regard, analyses of the Iba-1/
OPN ratio showed that Iba-1 levels were significantly lower in
all of the disease groups compared to the control.
This study is the first to show that OPN is also significantly
elevated in activated microglia in ALS. The rod-like shape of
microglia seen in this study has been recently reported in a rat
model of brain injury (Ziebell et al. 2012) and was seen earlier
in a model of experimental autoimmune encephalomyelitis or
neuritis (Schluesener et al. 1998). Additional studies with a
larger sample set and at different disease stages are required to
determine whether the increase in OPN displays a temporal
pattern. Interestingly, a recent study found that CD44, the
receptor for OPN, is elevated in the SOD1 mouse model for
familial ALS (Matsumoto et al. 2012). A connection between
disease progression, deficits in executive function, and high
levels of microglial activation has been found in ALS and is of
relevance as this area of cognitive functioning is also compro-
mised in HIV-infected individuals (Brettschneider et al.
2012a; Brettschneider et al. 2012b)
Our data revealed that in addition to microglia, neurons in
HAND are a major source of OPN. Levels of OPN were
highest in the HIV+ ANI group. This difference was not re-
lated to the overall levels of NeuN, as they were similar in the
HIV+ ANI and HIV+ MND/HAD groups. A possible limita-
tion is the small sample size as outliers could skew the results.
In a prior study, we found that OPN levels in CSF were ele-
vated in HIV-infected individuals with normal cognition and
further increased with a higher level of impairment (Brown
et al. 2011). Increases in OPN in the CSF, and specifically in
neurons, have been reported in neurodegenerative disorders
including multiple sclerosis, Alzheimer’s and Parkinson’s dis-
eases, frontotemporal dementia, and in models of brain injury
and stroke. In multiple sclerosis, elevations in CSF OPN are
associated with worse disease outcomes and may be related to
the ability of the cytokine to promote the survival of myelin
reactive T cells (Hur et al. 2006; Vogt et al. 2004). In contrast,
OPN perhaps acting through similar prosurvival pathways
promotes wound healing and repair after ischemic injury
(Chen et al. 2011; van Velthoven et al. 2011).
Our data provide support for the indirect pathway leading
to neuronal damage and dysfunction in HIV-associated infec-
tion of the CNS. The trafficking of HIV-infected and activated
macrophages, which are expressing OPN at a high level, sug-
gests that the elevation of this cytokine in the brain would be
an early event. Indeed, we found that HIV-infected individuals
(without cognitive impairment) had higher levels of OPN than
uninfected controls and those with MS (Brown et al. 2011).
Inflammation in the brain is required for repair and normal
homeostatic clearance activity. However, when inflammation
is sustained over a long period of time, and at excessive levels,
182 J. Neurovirol. (2015) 21:174–185
over activation of immune and CNS cells occur that leads, by
mechanisms that remain to be fully elucidated, to functional
dysregulation in which biological processes fail to behave in a
normal fashion leading to cellular degeneration and death.
Indeed, microglia play key roles in regulating neuronal cell
death, neurogenesis, and synaptic interactions. Crosstalk
through fractalkine receptor- and CD200 receptor-ligand in-
teractions between neurons and microglia serve to regulate the
inflammatory response and functional activity of these cells
(Katsumoto et al. 2014).
Western blot analyses on brain cell lysates and ELISA
measurements on CSF on samples from individuals with
HAND revealed significant elevation in OPN that trended
with the increase in cognitive impairment (Brown et al.
2011). This current study now demonstrates that the source
of OPN is multifactorial coming from astrocytes, resident
macrophage/microglia, and neurons. This finding expands
our thinking about the possible autocrine and paracrine feed-
back mechanisms that can operate in the brain parenchyma to
sustain OPN levels at this site. Moreover, astrocytes, microg-
lia, and neurons all express the receptors for OPN, which
include specific integrins and variants of CD44 (Ailane et al.
2013; Akiyama et al. 1993). OPN is a proinflammatory cyto-
kine of the innate immune system that primes several down-
stream factors in the inflammatory cascade. Studies investi-
gating the impact of OPN on the function of cells of the CNS
in the context of HIV infection will allow us to discern wheth-
er downregulation of OPN would provide any therapeutic
benefit.
Materials and methods
Patient samples and selection criteria
The study protocol was approved by the Johns Hopkins
Institutional Review Board. Tissue sections prepared from
the occipital lobe were obtained from the National
NeuroAIDS Tissue Consortium (NNTC). This region of the
brain has been previously shown to have abundant HIV infec-
tion and pathology. Cytomegalovirus encephalitis, toxoplas-
mosis (active and healed), aseptic leptomeningitis, bacterial
leptomeningitis, lymphoma, contusions, focal infarcts,
anoxic/ischemic damage, and tuberculosis were all excluded.
In addition, for all past and current substance-induced major
depressive disorder, cannabis, cocaine, opiate, and methadone
use were excluded. Toxicology reports were examined and
drug abuse and dependence were also excluded. All races as
well as medically prescribed drugs were allowed. The revised
American Academy of Neurology criteria were used to clas-
sify individuals into three groups based on cognitive function:
asymptomatic neurocognitive impairment (ANI), HIV-
associated mild neurocognitive disorder (MND), and HIV-
associated dementia (HAD) (Antinori et al. 2007). Query of
the NNTC database suggested that neurocognitive diagnosis
consistent at the last two visits prior to death and the combi-
nation of MND and HAD subjects would yield the required
number of cases. There were four groups examined: (1) HIV-
uninfected normal controls (normal, n=9); (2) neurocognitive
disorder other, amyotrophic lateral sclerosis (ALS, n=5); (3)
HIV-infected asymptomatic neurocognitive impairment (ANI,
n=5); and (4) HIV-infected minor neurocognitive disorder/
HIV-associated dementia (MND/HAD, n=9). Case number
10 was included in the MND/HAD group based on the detec-
tion of HIV encephalitis (HIVE) on neuropathological
examination.
Immunohistochemical staining
Paraffin-embedded sections were heated for 10 min at 60 °C,
then immersed in histoclear (Electron Microscopy Sciences)
twice for 10 min each, followed by a 100, 95, and 70 % eth-
anol gradient for a total of 10 min each. Slides were rinsed in
1× Tris-buffered saline (TBS) buffer (20 mM Tris, 13.8 mM
NaCl, pH 7.4) and then treated with proteinase K solution
(IHC World) for 20 min at 37 °C in a humidified chamber.
Depending on the antibody, slides were immersed in antigen
retrieval buffer (10 mMTris, 1 mMEDTA, 0.05 % Tween-20,
pH 9.0) or citric buffer (10 mM sodium citrate, 0.05% Tween-
20, pH 6.0) and placed in a steamer for 45 min. Slides were
incubated for 1 h in 10 % goat serum/TBS followed by incu-
bation with 1:100 dilution of rabbit anti-NeuN antibody
(ABN78, Millipore), rabbit anti-GFAP (AB5804, Millipore),
1:50 rabbit anti-AIF-1 (HPA049234, SIGMA-Aldrich), and
1:50 rabbit anti-CD68 (bs-1432R, Bioss) at 4 °C overnight.
The slides were rinsed thoroughly in 1× TBS followed by
incubation in 1:500 dilution of goat anti-rabbit-alkaline phos-
phatase antibody (7054, Cell Signaling) at room temperature
for 1 h. Slides were rinsed in 1× TBS and developed with
Permanent Fast-Red Quanto as directed by the manufacturer
(Thermo Scientific) for 10–15 min at room temperature. The
slides were rinsed in 1× TBS and treated with 3 % hydrogen
peroxide for 5–10min and rinsed then incubated with 1:100 of
mouse anti-OPN (MAB194P,Maine Biotechnology) for 1 h at
room temp. Slides were rinsed in 1× TBS then incubated with
1:1500 dilution of anti-mouse HRP (7076S, Cell Signaling)
for 1 h at room temperature. Slides were developed with DAB
peroxidase substrate kit (Vector) for 2 min, dehydrated, and
mounted in Cytoseal 60 (Thermo Scientific).
Data and statistical analyses
Ten or twenty images from all four quadrants of the slides
were taken at ×20 (Zeiss Axio Observer A1 inverted micro-
scope). The total area quantified was kept constant for each
section analyzed. Adjustment of the image brightness,
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contrast, and sharpness was performed with Adobe Photoshop
5.5 using the same settings for each image. The images were
saved as a new jpg file at a resolution of 300 dpi. The images
were then opened in ImageJ and the colors split (Fig. 5) and
pixel intensity quantified using the threshold function to select
the outline of the cells of interest and measurement function to
determine the area fraction of intensity. The total area exam-
ined for each sample remained constant. The area fractions
determined from ImageJ were imported into GraphPad
Prism 6 and analyzed by one-way ANOVA and Tukey’s cor-
rection for multiple comparisons with significance of p<0.05.
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